Tan Jiufeng, Wang Yao, Sun Lihui, Xu Siqi, Li Charles, Jin Xuefei
2nd Inpatient Area of Urology Department, China-Japan Union Hospital of Jilin University, Changchun, China.
Key Laboratory of Urology Tumor of Jilin Province, Changchun, China.
Front Cell Dev Biol. 2022 Jul 12;10:950241. doi: 10.3389/fcell.2022.950241. eCollection 2022.
Bladder cancer is the most common malignant tumor of the urinary system. Bladder cancer stem cells (BCSCs) play key roles in tumor initiation, metastasis, relapse and drug-resistance. Investigation of BCSCs is of great value. On the basis of a review of normal bladder stem cells and universal cancer stem cells (CSCs), we summarize the origin of BCSCs, isolation and identification of CSCs from bladder cancer, signaling pathway of BCSCs, BCSCs targeted therapy, and relationship of BCSCs with non-muscle invasiveness and muscle invasiveness. This review aims to provide better elucidation about BCSCs, and provide constructive data for classification, prognosis, treatment and early intervention of bladder cancer.
膀胱癌是泌尿系统最常见的恶性肿瘤。膀胱癌细胞（BCSCs）在肿瘤的起始、转移、复发和耐药性方面起着关键作用。对BCSCs的研究具有重要价值。在回顾正常膀胱干细胞和通用癌症干细胞（CSCs）的基础上，我们总结了BCSCs的起源、从膀胱癌中分离和鉴定CSCs、BCSCs的信号通路、BCSCs靶向治疗以及BCSCs与非肌层浸润性和肌层浸润性的关系。本综述旨在更好地阐明BCSCs，并为膀胱癌的分类、预后、治疗和早期干预提供建设性数据。
